Treatment failure (need to restart phototherapy or exchange transfusion or both) · neonatal jaundice
1 finding from 1 review
Duration of phototherapy (hours) · newborn infants with unconjugated hyperbilirubinaemia
Phototherapy with LED showed no clear difference in duration of phototherapy hours compared with non‐LED light source (high certainty).
1 finding from 1 review
Rate of decline of serum bilirubin (micromol/L/hr) · neonatal jaundice
1 finding from 1 review
Bilirubin‐induced brain dysfunction (defined as either the pathological finding of deep‐yellow staining of neurons and neuronal necrosis of the basal ganglia and brainstem nuclei or acute or chronic neurological deficit including athetoid cerebral... · neonatal jaundice
1 finding from 1 review
Mortality (all cause) · neonatal jaundice
1 finding from 1 review
Decline in bilirubin at 4 to 8 hours (μmol/L) · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Decline in serum bilirubin (over 24 hours) · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Exchange transfusion · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Acute life‐threatening events · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Parental satisfaction · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Breastfeeding ondischarge · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Rate of decline of serum bilirubin (micromol/L/hr) · newborn infants with unconjugated hyperbilirubinaemia
Phototherapy with LED showed no clear difference in rate of decline of serum total bilirubin mg/dL/hour compared with non‐LED light source (high certainty).
1 finding from 1 review
Use of ET (≥ 1); all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of ET (≥ 1); all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Use of ET (≥ 1); placebo‐controlled studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of ET (≥ 1); placebo‐controlled studies compared with phototherapy alone (moderate certainty).
1 finding from 1 review
ETs performed per infant; all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
ETs performed per infant; placebo‐controlled studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
Use of top‐up transfusion in 1st week of life; all studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of top‐up transfusion in 1st week of life; all studies compared with phototherapy alone (low certainty).
1 finding from 1 review
Use of top‐up transfusion after 1st week of life; all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of top‐up transfusion after 1st week of life; all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Maximum total serum bilirubin (µmol/L); all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
Duration of phototherapy (hours) · term and preterm neonates with hyperbilirubinaemia
1 finding from 1 review